Experimental Adjustment on Drug Interactions through Intestinal CYP3A Activity in Rat: Impacts of Kampo Medicines Repeat Administered

Table 2

Effects of oral pre-treatment with Hochuekkito or Saireito on the pharmacokinetic parameters of nifedipine after i.v. or i.j. administration to rats.

Parameter	Control	Hochuekkito	Saireito
i.v.
AUC0-∞ (𝜇g mL^−1	745 ± 129	807 ± 76	840 ± 91
min^−1)
𝑡1/2 (min)	37.4 ± 3.6	41.4 ± 4.9	35.0 ± 6.7
MRT	37.3 ± 3.6	47.2 ± 8.0	41.4 ± 7.2
i.j.
𝐶max (𝜇g mL^−1)	5.88 ± 0.61	4.12 ± 0.52*	3.40 ± 0.52*
𝑇max (min)	22.5 ± 8.66	30.0 ± 21.2	15 ± 0
AUC0-∞ (𝜇g mL^−1	421 ± 56	285 ± 55*	215 ± 54*
min^−1)
𝑡1/2 (min)	37.1 ± 5.4	41.9 ± 5.3	41.8 ± 2.5
MRT (min)	58.4 ± 8.3	60.0 ± 4.8	54.8 ± 5.1
F (%)	56.6 ± 7.6	35.3 ± 6.8*	25.6 ± 6.4*

Each value represents the mean ± SD of 4 or 5 rats.
The nifedipine solution (3 mg/kg) was intravenously (i.v.) or intrajejunal (i.j.) administrated to rats after 7 days pre-treatment with Hochuekkito or Saireito. ^∗𝑃<.05 compared with control.